Evidence map›Paper›PMID 29987499›Full record

ReviewCurrent heart failure reports2018

Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?

Agata Bielecka-Dabrowa, Breno Godoy, Joerg C Schefold, Michael Koziolek, Maciej Banach, Stephan von Haehling

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. How to interpret serum creatinine increases during decongestion.Frontiers in cardiovascular medicine · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Agata Bielecka-DabrowaDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland.
Breno GodoyDepartment of Cardiology and Pneumology, University of Göttingen Medical Centre, Robert-Koch-Strasse 40, 37075, Göttingen, Germany.
Joerg C SchefoldDepartment of Intensive Care Medicine, Inselspital Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
Michael KoziolekDepartment of Nephrology and Rheumatology, University Medical Centre Göttingen, Göttingen, Germany.
Maciej BanachDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland.
Stephan von HaehlingDepartment of Cardiology and Pneumology, University of Göttingen Medical Centre, Robert-Koch-Strasse 40, 37075, Göttingen, Germany. stephan.von.haehling@web.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAcute decompensated heart failure (ADHF) is one of the biggest challenges in the management of chronic heart failure. Despite several advances in medical and device therapy, high readmission and mortality rates continue to be a burden on healthcare systems worldwide. The aim of the current review is to provide an overview on current as well as future approaches in cardiorenal interactions in patients with ADHF. RECENT

findingsOne of the strongest predictors of adverse outcomes in ADHF is renal dysfunction, referred to as cardiorenal syndromes (CRS) or cardiorenal interactions. Patients with ADHF frequently develop worsening of renal function (WRF) and/or acute kidney injury (AKI). Recent studies brought new information about biomarkers in diagnosing and predicting prognosis of CRS. Among others, dry weight at hospital discharge is considered a surrogate marker of successful treatment in ADHF patients with/without renal dysfunction. The etiology of WRF appears to be an important factor for determining risk related to WRF as well as clinical management. The hypertonic saline used as adjunctive therapy for intravenous loop diuretics and/or induction of aquaresis (e.g., using tolvaptan) may be promising and efficient approaches in the future.

Indexed as

Acute DiseaseAcute Kidney InjuryBiomarkersHeart FailureHumansKidney Function TestsNatriuretic Peptide, BrainRisk FactorsBiomarkersNatriuretic Peptide, BrainAcute decompensated heart failureBiomarkersCardiorenal interactionsCardiorenal syndromeHypertonic saline solutionTolvaptan

Identifiers

PMID29987499

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.